Enzon Pharmaceuticals, Inc. (ENZN)

OTCMKTS: ENZN · Delayed Price · USD
+0.080 (21.86%)
Aug 8, 2022 4:00 PM - Market closed

Company Description

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products.

The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

Enzon Pharmaceuticals, Inc.
Enzon Pharmaceuticals Logo
Country United States
Founded 1981
IPO Date Feb 15, 1984
Industry Biotechnology
Sector Health Care
CEO Andrew Rackear

Contact Details

20 Commerce Drive, Suite 135
Cranford, New Jersey 07016
United States
Phone 732 980 4500
Website enzon.com

Stock Details

Ticker Symbol ENZN
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0000727510
CUSIP Number 293904108
ISIN Number US2939041081
Employer ID 22-2372868
SIC Code 2836

Key Executives

Name Position
Richard L. Feinstein Chief Executive Officer, Chief Financial Officer and Company Secretary

Latest SEC Filings

Date Type Title
Jun 21, 2022 3 Initial statement of beneficial ownership of securities
Jun 15, 2022 8-K Current report
Apr 26, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
Apr 22, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 22, 2022 DEF 14A Other definitive proxy statements
Feb 25, 2022 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
Nov 5, 2021 10-Q Quarterly report [Sections 13 or 15(d)]
Aug 17, 2021 4 Statement of changes in beneficial ownership of securities
Aug 5, 2021 10-Q Quarterly report [Sections 13 or 15(d)]
Jun 8, 2021 8-A12G/A Registration of securities [Section 12(g)]